Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

Isla M. Johnson; Omer Karrar; Masooma Rana; Moazah Iftikhar; Sunny Chen; Kristen McCullough; Antoine N. Saliba; Aref Al-Kali; Hassan Alkhateeb; Kebede Begna; Mark Litzow; William J. Hogan; Mithun Shah; Mrinal M. Patnaik; Animesh Pardanani; Joerg Hermann; Ayalew Tefferi; Naseema Gangat

doi:10.1111/bjh.19325

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

Isla M. Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N. Saliba, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Mark Litzow, William J. Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Joerg Hermann, Ayalew Tefferi, Naseema Gangat

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non-ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A-mutated cases less likely (p < 0.01) to be affected. Treatment-emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination.

Original language	English (US)
Pages (from-to)	1232-1237
Number of pages	6
Journal	British journal of haematology
Volume	204
Issue number	4
DOIs	https://doi.org/10.1111/bjh.19325
State	Published - Apr 2024

Keywords

heart failure
leukaemia
pericarditis
venetoclax

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.19325

Cite this

Johnson, I. M., Karrar, O., Rana, M., Iftikhar, M., Chen, S., McCullough, K., Saliba, A. N., Al-Kali, A., Alkhateeb, H., Begna, K., Litzow, M., Hogan, W. J., Shah, M., Patnaik, M. M., Pardanani, A., Hermann, J., Tefferi, A., & Gangat, N. (2024). Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. British journal of haematology, 204(4), 1232-1237. https://doi.org/10.1111/bjh.19325

Johnson, IM, Karrar, O, Rana, M, Iftikhar, M, Chen, S, McCullough, K, Saliba, AN, Al-Kali, A, Alkhateeb, H, Begna, K , Litzow, M , Hogan, WJ, Shah, M, Patnaik, MM , Pardanani, A, Hermann, J, Tefferi, A & Gangat, N 2024, 'Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents', British journal of haematology, vol. 204, no. 4, pp. 1232-1237. https://doi.org/10.1111/bjh.19325

@article{9dec424d774349f7aad973ffe9743d05,

title = "Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents",

abstract = "Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non-ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A-mutated cases less likely (p < 0.01) to be affected. Treatment-emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination.",

keywords = "heart failure, leukaemia, pericarditis, venetoclax",

author = "Johnson, {Isla M.} and Omer Karrar and Masooma Rana and Moazah Iftikhar and Sunny Chen and Kristen McCullough and Saliba, {Antoine N.} and Aref Al-Kali and Hassan Alkhateeb and Kebede Begna and Mark Litzow and Hogan, {William J.} and Mithun Shah and Patnaik, {Mrinal M.} and Animesh Pardanani and Joerg Hermann and Ayalew Tefferi and Naseema Gangat",

note = "Publisher Copyright: {\textcopyright} 2024 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2024",

month = apr,

doi = "10.1111/bjh.19325",

language = "English (US)",

volume = "204",

pages = "1232--1237",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

AU - Johnson, Isla M.

AU - Karrar, Omer

AU - Rana, Masooma

AU - Iftikhar, Moazah

AU - Chen, Sunny

AU - McCullough, Kristen

AU - Saliba, Antoine N.

AU - Al-Kali, Aref

AU - Alkhateeb, Hassan

AU - Begna, Kebede

AU - Litzow, Mark

AU - Hogan, William J.

AU - Shah, Mithun

AU - Patnaik, Mrinal M.

AU - Pardanani, Animesh

AU - Hermann, Joerg

AU - Tefferi, Ayalew

AU - Gangat, Naseema

PY - 2024/4

Y1 - 2024/4

N2 - Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non-ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A-mutated cases less likely (p < 0.01) to be affected. Treatment-emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination.

AB - Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non-ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four patients had more than one cardiac complication. Baseline characteristics included median age ± interquartile range; 73 ± 5 years; 87% males; 96% with cardiovascular risk factors; and 90% with preserved baseline ejection fraction. In multivariate analysis, males were more likely (p = 0.02) and DNMT3A-mutated cases less likely (p < 0.01) to be affected. Treatment-emergent cardiac events were associated with a trend towards lower composite remission rates (43% vs. 62%; p = 0.09) and shorter survival (median 7.7 vs. 13.2 months; p < 0.01). These observations were retrospectively retrieved and warrant further prospective examination.

KW - heart failure

KW - leukaemia

KW - pericarditis

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85184242855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85184242855&partnerID=8YFLogxK

U2 - 10.1111/bjh.19325

DO - 10.1111/bjh.19325

M3 - Article

AN - SCOPUS:85184242855

SN - 0007-1048

VL - 204

SP - 1232

EP - 1237

JO - British journal of haematology

JF - British journal of haematology

IS - 4

ER -

Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this